一种用于野生型p53癌症治疗的三重作用的PROTAC
Gregory H Bird1, Utsarga Adhikary1, Michael J Schmidt1
1Department of Pediatric Oncology and Chemical Biology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Cell reports. Medicine
|November 27, 2025
概括
一种新型的三重作用蛋白溶解向嵌合体 (TAPTAC1) 通过降解瘤原蛋白和阻止封存来重新激活p53癌症疗法. 在野生类型的p53癌症中,TAPTAC1显示出卓越的疗效和降低的毒性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 抑制p53在癌症中至关重要,但治疗性重新激活面临有效性和毒性挑战.
- 现有的治疗方法,如向化疗和组合化疗,在治疗野生型p53癌症方面存在局限性.
- 针对蛋白质溶解的嵌合体 (PROTACs) 为向蛋白质降解提供了一个有前途的途径.
研究的目的:
- 开发一种用于在癌症中重新激活p53的新疗法.
- 引入三重作用蛋白溶解向金氏体 (TAPTAC) 以克服当前癌症疗法的局限性.
- 在临床前癌症模型中评估TAPTAC1的疗效和安全性.
主要方法:
- 设计和合成TAPTAC1,一种被设计成同时向多个致癌途径的分子.
- 在体外和体内研究使用癌细胞系和小鼠模型 (骨肉瘤,白血病) 野生型p53.
- 对TAPTAC1与现有的组合治疗和单向PROTAC进行比较分析.
主要成果:
- TAPTAC1通过将HDM2从p53降解中转移并消除瘤性BET蛋白来有效地重新激活p53.
- TAPTAC1阻断了HDMX介导的p53封存,增强了p53的活性和亡.
- 与组合疗法和HDM2/BET向PROTAC相比,TAPTAC1在WT p53癌症中显示出更高的疗效和更低的毒性.
- 该药物利用癌症对HDM2的依赖来提高选择性和安全性.
结论:
- TAPTACs代表了治疗野生类型p53癌症的有希望的治疗平台,解决了先前策略的局限性.
- TAPTAC1提供了一种新的方法,可以同时向多种瘤机制,以有效治疗癌症.
- 在儿童和成人癌症中保留WT p53的广泛适用性突显了TAPTACs的潜力.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


